Beta Drugs P/E Ratio
Beta Drugs (BETA) P/E ratio is 55.82 (High), EPS (TTM) ₹40.92, current price ₹2315.60 on NSE vs historical average P/E of 39.87 (100.0th percentile) — Very High - High growth expectations or significantly overvalued. Read Beta Drugs dividend payments for the complete payout history and dividend yield track record.
Current Valuation Metrics
Valuation Signal
Sector Context
Earnings Breakdown (TTM)
BETA P/E Ratio — Valuation Signal & Historical Context
Beta Drugs P/E 55.82 vs historical average 39.87, range 39.87–39.87 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see BETA share price.
- Stock appears overvalued with PE of 55.82, suggesting caution for new investments
- Current PE is 40.0% above historical average
Beta Drugs P/E Ratio Historical Trend
BETA annual price-to-earnings ratio — 1 years, EPS and year-end price. Current P/E 55.82 vs historical average 39.87. See Beta Drugs P/B valuation to compare market price against book value per share.
BETA Historical P/E Ratio — EPS, Year-End Price & Valuation
Beta Drugs annual P/E ratio, EPS (₹), year-end price and valuation category on NSE.
| Year | P/E Ratio | EPS (₹) | Year-end Price (₹) | Exchange | Valuation |
|---|---|---|---|---|---|
| 2025 | 39.87 | 41.49 | ₹1654.00 | NSE | High |
BETA vs Healthcare Peers — P/E Ratio Comparison
Beta Drugs P/E 55.82 vs Healthcare average 55.64, median 31.4 — range 2.86–916.67.
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.61 | ₹64 | Low |
| Sunrest Lifescience | SUNREST | 3.76 | ₹30 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.76 | ₹7,399 | Low |
| Shelter Pharma | SHELTER | 5.23 | ₹47 | Low |
| Dipna Pharmachem | DPL | 5.39 | ₹14 | Low |
| JFL Life Sciences | JFLLIFE | 5.41 | ₹68 | Low |
| Amwill Health Care | AMWILL | 7.26 | ₹83 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹84 | Low |
| Galaxy Medicare | GML | 7.8 | ₹27 | Low |